Persist AI vs Bucket Robotics

About

Persist AI is a pharmaceutical formulation company operating an AI-powered drug formulation platform with robotic cloud lab capabilities — specializing in the development of long-acting injectable (LAI) microsphere formulations that can deliver drug release over weeks or months (up to one year), addressing the adherence challenges of daily oral medications for chronic conditions including mental health, addiction, HIV, contraception, and oncology. Founded in 2022 and backed by $16 million including a $12 million Series A led by Spero Ventures with participation from Eli Lilly, Persist AI accelerates drug development timelines by approximately 50%, reducing typical 5-year formulation development to 2 years.\n\nPersist AI's platform combines AI-driven formulation design (predicting which polymer/drug/process combinations will achieve target release profiles) with robotic laboratory execution (automated synthesis and testing of formulation candidates) and analytics that identify optimal formulations faster than traditional trial-and-error approaches. The microsphere technology encapsulates drug molecules in biodegradable polymer spheres that gradually release the drug as the polymer degrades — a proven technology (Risperdal Consta, Lupron Depot) but one that takes years to develop with traditional methods. Eli Lilly's participation as an investor signals pharma validation of the platform approach.\n\nIn 2025, Persist AI competes in the drug formulation and CDMO (contract development and manufacturing) market with EVO Pharma, Polymeropoulos (a long-acting injectable specialist), and larger CDMOs including Lonza and Catalent for LAI microsphere development services. The long-acting injectable market is growing as mental health conditions (schizophrenia, bipolar) see improved outcomes with LAI antipsychotics that eliminate the adherence problem — patients who receive monthly or quarterly injections have significantly better medication compliance than those taking daily pills. The 2025 strategy focuses on growing pharma company partnerships for LAI development projects, advancing internal pipeline candidates toward clinical trials, and building the manufacturing scale-up capabilities needed for commercial supply.